Evaxion Biotech AS (EVAX)
1.49
+0.12
(+8.76%)
USD |
NASDAQ |
Nov 22, 16:00
1.42
-0.07
(-4.70%)
After-Hours: 20:00
Evaxion Biotech Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2022 | -0.30M |
| March 31, 2022 | 7.738M |
| December 31, 2021 | 24.65M |
| September 30, 2021 | -0.065M |
| June 30, 2021 | -0.035M |
| Date | Value |
|---|---|
| March 31, 2021 | 25.25M |
| December 31, 2020 | 2.374M |
| September 30, 2020 | 6.479M |
| June 30, 2020 | -0.018M |
| March 31, 2020 | -0.018M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.30M
Minimum
Jun 2022
25.25M
Maximum
Mar 2021
6.606M
Average
1.178M
Median
Cash from Financing (Quarterly) Benchmarks
| Ascendis Pharma AS | -- |
| DBV Technologies SA | 0.007M |
| Adaptimmune Therapeutics PLC | 25.00M |
| Akari Therapeutics PLC | -0.443M |
| Biodexa Pharmaceuticals PLC | -- |
Cash from Financing (Quarterly) Related Metrics
| Free Cash Flow Yield | -361.0% |